{"id":"https://openalex.org/W3022266387","doi":"https://doi.org/10.1097/mnm.0000000000001205","title":"Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience","display_name":"Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience","publication_year":2020,"publication_date":"2020-05-01","ids":{"openalex":"https://openalex.org/W3022266387","doi":"https://doi.org/10.1097/mnm.0000000000001205","mag":"3022266387","pmid":"https://pubmed.ncbi.nlm.nih.gov/32371670"},"language":"en","primary_location":{"id":"doi:10.1097/mnm.0000000000001205","doi":"https://doi.org/10.1097/mnm.0000000000001205","is_oa":false,"landing_page_url":"https://doi.org/10.1097/mnm.0000000000001205","pdf_url":null,"source":{"id":"https://openalex.org/S108023290","display_name":"Nuclear Medicine Communications","issn_l":"0143-3636","issn":["0143-3636","1473-5628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nuclear Medicine Communications","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027749819","display_name":"Swayamjeet Satapathy","orcid":"https://orcid.org/0000-0001-5318-6644","observed_orcids":["https://orcid.org/0000-0001-5318-6644"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Swayamjeet Satapathy","raw_affiliation_strings":["Nuclear Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053724034","display_name":"Bhagwant Rai Mittal","orcid":"https://orcid.org/0000-0002-0016-5783","observed_orcids":["https://orcid.org/0000-0002-0016-5783"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bhagwant Rai Mittal","raw_affiliation_strings":["Nuclear Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069230648","display_name":"Ashwani Kumar Sood","orcid":"https://orcid.org/0000-0001-7228-0361","observed_orcids":["https://orcid.org/0000-0001-7228-0361"]},"institutions":[{"id":"https://openalex.org/I45294948","display_name":"Post Graduate Institute of Medical Education and Research","ror":"https://ror.org/009nfym65","country_code":"IN","type":"education","lineage":["https://openalex.org/I45294948"]}],"countries":["IN"],"is_corresponding":true,"raw_author_name":"Ashwani Sood","raw_affiliation_strings":["Nuclear Medicine","fax: +91 172 2742858","to Ashwani Sood, DNB, Department of Nuclear Medicine, PGIMER, Chandigarh 160012, India, Tel: +91 172 2756728"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine","institution_ids":[]},{"raw_affiliation_string":"fax: +91 172 2742858","institution_ids":[]},{"raw_affiliation_string":"to Ashwani Sood, DNB, Department of Nuclear Medicine, PGIMER, Chandigarh 160012, India, Tel: +91 172 2756728","institution_ids":["https://openalex.org/I45294948"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047090799","display_name":"Roshan Kumar Verma","orcid":"https://orcid.org/0000-0001-6560-8875","observed_orcids":["https://orcid.org/0000-0001-6560-8875"]},"institutions":[{"id":"https://openalex.org/I45294948","display_name":"Post Graduate Institute of Medical Education and Research","ror":"https://ror.org/009nfym65","country_code":"IN","type":"education","lineage":["https://openalex.org/I45294948"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Roshan Verma","raw_affiliation_strings":["Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India","institution_ids":["https://openalex.org/I45294948"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112543595","display_name":"Naresh Panda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I45294948","display_name":"Post Graduate Institute of Medical Education and Research","ror":"https://ror.org/009nfym65","country_code":"IN","type":"education","lineage":["https://openalex.org/I45294948"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Naresh Panda","raw_affiliation_strings":["Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India","institution_ids":["https://openalex.org/I45294948"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5069230648"],"corresponding_institution_ids":["https://openalex.org/I45294948"],"apc_list":null,"apc_paid":null,"fwci":1.8485,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":{"value":0.85431464,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"41","issue":"7","first_page":"629","last_page":"635"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9398999810218811,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.035999998450279236,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.014000000432133675,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/medullary-thyroid-carcinoma","display_name":"medullary thyroid carcinoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/177lu-dotatate","display_name":"177Lu-DOTATATE","score":0.9290000200271606},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9470000267028809},{"id":"https://openalex.org/keywords/peptide-receptor-radionuclide-therapy","display_name":"peptide receptor radionuclide therapy","score":0.9879999756813049},{"id":"https://openalex.org/keywords/concomitant-chemotherapy","display_name":"concomitant chemotherapy","score":0.5820000171661377},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.8569999933242798},{"id":"https://openalex.org/keywords/metastatic-thyroid-carcinoma","display_name":"metastatic thyroid cancer","score":0.7480000257492065},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.6990000009536743}],"concepts":[{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.9000823497772217},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8709994554519653},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.7700855731964111},{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.6739457249641418},{"id":"https://openalex.org/C2780120053","wikidata":"https://www.wikidata.org/wiki/Q3493538","display_name":"Medullary thyroid cancer","level":4,"score":0.5535455942153931},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5321418642997742},{"id":"https://openalex.org/C2993294228","wikidata":"https://www.wikidata.org/wiki/Q13632630","display_name":"Thyroid carcinoma","level":3,"score":0.5016992092132568},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.482372909784317},{"id":"https://openalex.org/C151032500","wikidata":"https://www.wikidata.org/wiki/Q5194182","display_name":"Cumulative dose","level":2,"score":0.47983333468437195},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.46584829688072205},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.36240488290786743},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3613564372062683},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35861140489578247},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.34104883670806885},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.3361729383468628},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2670901417732239},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2405591905117035},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009942","descriptor_name":"Organometallic Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D009942","descriptor_name":"Organometallic Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D018278","descriptor_name":"Carcinoma, Neuroendocrine","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D023381","descriptor_name":"Endpoint Determination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/mnm.0000000000001205","doi":"https://doi.org/10.1097/mnm.0000000000001205","is_oa":false,"landing_page_url":"https://doi.org/10.1097/mnm.0000000000001205","pdf_url":null,"source":{"id":"https://openalex.org/S108023290","display_name":"Nuclear Medicine Communications","issn_l":"0143-3636","issn":["0143-3636","1473-5628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nuclear Medicine Communications","raw_type":"journal-article"},{"id":"pmid:32371670","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32371670","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nuclear medicine communications","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W42253793","https://openalex.org/W1530027230","https://openalex.org/W1988986189","https://openalex.org/W2005907891","https://openalex.org/W2006830353","https://openalex.org/W2024998464","https://openalex.org/W2027729777","https://openalex.org/W2030980488","https://openalex.org/W2046559346","https://openalex.org/W2119501407","https://openalex.org/W2120139412","https://openalex.org/W2122956665","https://openalex.org/W2128544796","https://openalex.org/W2137385634","https://openalex.org/W2179612320","https://openalex.org/W2753761135","https://openalex.org/W2795287337","https://openalex.org/W2803958500","https://openalex.org/W2897851894","https://openalex.org/W2917068635","https://openalex.org/W2919349289","https://openalex.org/W2942964653","https://openalex.org/W6631797190","https://openalex.org/W7073923215"],"related_works":["https://openalex.org/W2063336005","https://openalex.org/W7130544989","https://openalex.org/W7127562082","https://openalex.org/W4296180048","https://openalex.org/W2991476753","https://openalex.org/W4415518005","https://openalex.org/W7130393905","https://openalex.org/W7125827663","https://openalex.org/W2574457023","https://openalex.org/W4390490567"],"abstract_inverted_index":{"AIMS:":[0],"Peptide":[1],"receptor":[2],"radionuclide":[3],"therapy":[4,27],"(PRRT)":[5],"has":[6,28],"been":[7,31],"shown":[8],"to":[9,40,77,122,131,242],"be":[10,141],"useful":[11],"in":[12,33,50,135,143,160,181,190,196,207,216,232,254],"inoperable/metastatic":[13,68],"medullary":[14],"thyroid":[15],"carcinoma":[16],"(MTC).":[17],"However,":[18,164],"the":[19,42,169,183,201,223,244],"role":[20,245],"of":[21,46,63,66,104,124,148,176,203,227,246],"concomitant":[22,72,228],"PRRT":[23,126,253],"and":[24,44,82,87,90,115,174,225,230],"low-dose":[25],"capecitabine":[26,118,231,247],"not":[29],"yet":[30],"studied":[32],"these":[34,255],"patients.":[35,145,163,185,199,256],"This":[36,56],"study":[37],"was":[38,57,158,179,194,214],"conducted":[39],"evaluate":[41],"efficacy":[43,224],"safety":[45,226],"this":[47,217],"combination":[48],"approach":[49],"advanced":[51,67,97,233],"MTC.":[52,234],"MATERIALS":[53],"AND":[54],"METHODS:":[55],"a":[58,100,249],"retrospective,":[59],"single-centre":[60],"study.":[61],"Data":[62],"consecutive":[64],"patients":[65,95,150],"MTC":[69,98],"treated":[70],"with":[71,96,188,252],"Lu-DOTATATE+capecitabine,":[73],"from":[74,119],"January":[75],"2014":[76],"August":[78],"2018,":[79],"were":[80],"collected":[81],"analysed":[83],"for":[84,172],"radiological,":[85],"molecular":[86,165],"biochemical":[88],"responses":[89],"treatment-related":[91],"toxicity.":[92],"RESULTS:":[93],"Eight":[94],"received":[99],"median":[101],"cumulative":[102],"dose":[103],"20.9":[105],"GBq":[106],"(interquartile":[107],"range":[108],"8.9-27.7":[109],"GBq)":[110],"Lu-DOTATATE":[111,229],"over":[112],"1-4":[113],"cycles":[114],"1250":[116],"mg/m":[117],"days":[120],"0":[121],"14":[123],"each":[125],"cycle.":[127],"Radiological":[128],"response":[129,187],"according":[130],"Response":[132],"Evaluation":[133],"Criteria":[134],"Solid":[136],"Tumours":[137],"1.1":[138],"criteria":[139],"could":[140],"assessed":[142],"seven":[144,149,184],"Six":[146],"out":[147],"(86%)":[151],"had":[152],"stable":[153],"disease,":[154],"while":[155],"disease":[156],"progression":[157],"observed":[159,180,195,215],"1/7":[161],"(14%)":[162],"response,":[166],"as":[167,248],"per":[168],"European":[170],"Organization":[171],"Research":[173],"Treatment":[175],"Cancer":[177],"criteria,":[178],"all":[182],"Biochemical":[186],"reduction":[189],"serum":[191],"calcitonin":[192],"levels":[193],"3/5":[197],"(60%)":[198],"With":[200],"exception":[202],"grade":[204],"2":[205],"anaemia":[206],"one":[208],"patient,":[209],"no":[210],"other":[211],"significant":[212],"toxicity":[213],"cohort.":[218],"CONCLUSION:":[219],"Our":[220],"results":[221],"indicate":[222],"Larger":[235],"randomized":[236],"controlled":[237],"trials":[238],"are,":[239],"however,":[240],"required":[241],"establish":[243],"radiosensitizer":[250],"along":[251]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-05-13T00:00:00"}